IL6 and neoplasm: In line with our findings, IL1 and OSM have been implicated in cancer-associated inflammation and therapy resistance and research has shown that blocking IL1 and IL6 family of inflammatory cytokines could enhance anti-tumor activity in head and neck squamous cell carcinomas50–52.